Investing

Compass Pathways : CMPS

CMPS

Stock Data

$7.49

$0.12 (1.63%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

MEDICAL CARE FACILITIES

Compass Pathways Plc is a pioneering mental health care company based in London, focusing on creating innovative treatments. It is known for developing COMP360, a psilocybin therapy, which is currently undergoing advanced clinical trials. This therapy aims to address severe conditions such as treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa. Founded in 2020, Compass Pathways is at the forefront of exploring psychedelic-based treatments to improve mental health.

All Compass Pathways Articles

4 Articles

Lee Jackson | Jun 17, 2023 at 6:05 AM EDT

5 of Cathie Wood’s Sizzling ARK Investment Stocks Are Buy Rated and Trading Under $10

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential.…

Lee Jackson | Nov 2, 2022 at 8:55 AM EDT

Wednesday’s Top Analyst Upgrades and Downgrades: AppLovin, Charles Schwab, First Solar, Halliburton, Monster Beverage, QuantumScape, Union Pacific and More

Wednesday's top analyst upgrades and downgrades included AppLovin, Arista Networks, Charles Schwab, First Solar, Global Payments, Halliburton, Monster Beverage, NXP…

Chris Lange | Jan 25, 2022 at 7:35 AM EST

5 Psychedelic Therapeutics Decisions Coming in 2022

Here is a look of a few of the biggest clinical trial and FDA updates in regards to psychedelics to…

Paul Ausick | Sep 8, 2021 at 12:39 PM EDT

Time to Buy the Magic Stocks? Magic Mushrooms, That Is.

Here's a quick look at six publicly traded companies developing ways to use psychedelics to treat mental health issues.